Related Experiment Videos

Treatment of chronic hepatitis C in elderly patients

Y Horsmans1

  • 1Université catholique de Louvain, Cliniques Universitaires Saint-Luc, Department of Gastroenterology, 10, avenue Hippocrate, 1200 Brussels, Belgium. Yves.Horsmans@uclouvain.be

Expert Opinion on Pharmacotherapy
|February 19, 2010
PubMed

Insights

Elderly patients with chronic hepatitis C (HCV) have lower sustained virologic response (SVR) rates to antiviral therapy. Treatment decisions for older individuals should consider comorbidities and life expectancy, favoring younger treatment initiation.

Area of Science:

  • Hepatology
  • Geriatric Medicine
  • Viral Hepatitis Research

Background:

  • The aging population in Western countries presents a significant challenge for chronic hepatitis C (HCV) management.
  • HCV prevalence and the average age of affected patients are steadily increasing.

Purpose of the Study:

  • To review and analyze existing clinical studies on treating HCV in elderly patients.
  • To highlight the impact of age on treatment outcomes and therapeutic considerations.

Main Methods:

  • Systematic review of limited clinical studies focusing on HCV treatment in the elderly.
  • Analysis of factors influencing sustained virologic response (SVR) in older populations.

Main Results:

  • Advanced age is consistently associated with reduced SVR rates in HCV patients.
  • Elderly patients require consideration of comorbidities and life expectancy alongside traditional SVR parameters before treatment.
  • Antiviral therapy is recommended for selected elderly HCV patients with advanced fibrosis.

Conclusions:

  • Age is a critical factor influencing the success of antiviral therapy for HCV.
  • Further research is needed to optimize HCV treatment strategies for the elderly population.
  • Early initiation of antiviral treatment in younger patients is generally favored.
Abstract

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment: